News

The once-daily oral therapy Orladeyo (berotralstat) has been approved in Brazil to prevent swelling attacks in people, 12 and older, with hereditary angioedema (HAE). The approval by the Brazilian Health Regulatory Agency (ANVISA) makes Orladeyo the first oral prophylactic (preventive) therapy authorized for HAE patients in the country.

A 46-year-old woman with hard to treat idiopathic angioedema was successfully treated with the asthma and allergies medication omalizumab, which is sold as Xolair, according to a recent case study. “In the context of isolated [angioedema], even after failure of up-dosed antihistaminic therapy, a trial with omalizumab is…

A dozen new mutations in the SERPING1 gene were identified in Slovakia as the cause of hereditary angioedema (HAE) due to C1-inhibitor deficiency or dysfunction — known as C1-INH-HAE — according to a new study based on a complex analysis. That genetic analysis also suggested that the prevalence of…

The use of vaccines against SARS-CoV-2, the virus that causes COVID-19, was not linked to an increased risk of disease worsening in people with hereditary angioedema (HAE), according to a small, single-center study from Turkey. The study also found that the viral infection was not always associated with disease worsening…

Most people with hereditary angioedema (HAE) can usually predict an impending swelling attack based on early, or prodromal, signs or symptoms, according to an online survey. However, results showed differing behaviors and definitions for “early treatment,” with 60% of the participants taking medications as soon as early symptoms…

An 83-year-old woman suddenly developed angioedema of the airway as a result of neck trauma while being treated with telmisartan, a medication commonly used to lower blood pressure, according to a case report from the U.S. “This case report highlights the rare and often forgotten adverse reaction of angioedema…

Treatment with the experimental under-the-skin injection therapy STAR-0215 reduced the rates of monthly swelling attacks by more than 90% in people with hereditary angioedema (HAE) in a small early clinical trial. That’s according to new data announced by developer Astria Therapeutics, which further showed that HAE attacks…

Long-term daily treatment with Orladeyo (berotralstat) effectively reduced swelling attacks and improved patient-reported outcomes in Japanese adults with hereditary angioedema (HAE), according to data from a Phase 3 clinical trial. Findings were detailed in the study, “Berotralstat for long-term prophylaxis of hereditary angioedema in Japan: Parts 2…

Pharvaris has started a Phase 3 clinical trial called RAPIDe-3 to test an immediate-release capsule formulation of deucrictibant as an on-demand treatment to manage swelling attacks in hereditary angioedema (HAE). “We hear from the HAE community that rapid onset and complete resolution of angioedema attacks with a single,…

Treatment with tranexamic acid was safe and not linked to a higher risk of worse outcomes in people who developed angioedema after being on angiotensin-converting enzyme inhibitors (ACEIs), a type of blood pressure-lowering medication, a study finds. While initial findings suggested a link between tranexamic acid and greater rates…